 Although concurrent chemoradiation is the standard treatment modality for locally advanced nasopharyngeal carcinoma NPC, high incidences of distant metastases and severe treatment related toxicities have become an obstacle to be overcome. A phase II study conducted by Hui et al. showed that neoadjuvant chemotherapy followed by concurrent chemoradiotherapy was superior to the standard concomitant chemoradiation in terms of the 3-year OS without significantly exacerbating the acute toxicities. 